Hybio Pharmaceutical (Wuhan) Co., Ltd.
Hybio Pharmaceutical (Wuhan) Co., Ltd.
No. 9, Hengdian Street Linkongxi Street, Huangpi District, Wuhan, China
Overview
Founded in 1998 and listed on the Shenzhen Stock Exchange (300199) in 2011, Hybio Pharmaceutical is one of the earliest listed peptide drug companies in China. It is a national high-tech enterprise, focusing on the research and development, production and marketing of peptide drugs and small nucleic acid drugs, and layout of "innovative drugs + generic drugs" and CRDMO services. The company has a national-level platform such as the "National Local Joint Engineering Laboratory of Peptide Drugs", undertakes a number of national projects, and has won the second prize of the National Technology Invention Award and other honors. The quality system has passed multi-country GMP/cGMP certification such as China NMPA, US FDA, EU EMA, Brazil ANVISA, Australia TGA, Indonesia BPOM, South Korea MFDS. The Wuhan subsidiary (Linkong Demonstration Park in Huangpi District) is a special API production base for polypeptides. It is designed and built in accordance with international cGMP standards and equipped with a fully automatic polypeptide synthesis and purification system. It has passed the official GMP certification of China/the United States/Australia, and is expanding its API production line, with the goal of building a world-class polypeptide API base. The peptide API has now been sold to more than 20 countries and regions, and the preparation has been sold to more than 90 countries and regions. It has cooperated with international pharmaceutical companies such as Ferring, Hikma, and 3SBio Mandi, and has been first imitated/approved by the FDA in the United States.
Notes
Hybio Pharmaceutical (Wuhan) Co., Ltd. is located at No. 9, Hengdian Street Linkongxi Street, Huangpi District, Wuhan, China.
Finished peptide dosage forms available.
Website: https://www.hybio.com